biovu

June 29, 2022

Study shows genotype leads to discontinued, decreased medication

By Jill Clendening
June 16, 2022

BMI genetics influence heart function

Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.

By Leigh MacMillan
VUMC’s new automated biobanking system can store as many as 10 million biospecimens.
June 8, 2022

BioVU celebrates 15 years supporting personalized medicine

BioVU is celebrating its 15th year and has enabled hundreds of studies and publications exploring the genetic underpinnings of a host of conditions including cancer, heart disease and diabetes. 

By Lindsey Guerin
May 19, 2022

Genetics and blood pressure

Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

By Leigh MacMillan
May 19, 2022

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

By Joshua Baker
May 9, 2022

Gene variants and transplant drug dose

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

By Leigh MacMillan
May 5, 2022

Gene network linked to Type 2 diabetes

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.
By Joshua Baker
April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.
By Leigh MacMillan
January 10, 2022

Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development

Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
By Bill Snyder
December 2, 2021

Gene discoveries give new hope to people who stutter

New research shows the potential to identify therapeutic directions that could improve outcomes for people who stutter.
By Bill Snyder
September 1, 2021

Initiative helps physicians interpret genetic test results

A new institutional initiative will offer a secure and easy way for physicians at Vanderbilt University Medical Center to ask for help interpreting genetic test results for their patients.
By Nancy Humphrey
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.
By Bill Snyder
July 12, 2021

Probing statin-associated diseases with genetics

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.
By Leigh MacMillan
1 2 3 4 … 6